Overview

Welcome to Stayble Therapeutics AB´s IR pages

Stayble Therapeutics is a clinical pharmaceutical company developing an injection-based treatment against disc herniation. Stayble currently conducts a phase 1b within disc herniation.

LATEST PRESS RELEASES

January 31, 2025 Regulatorisk

(SV) – Stayble Therapeutics AB (publ) offentliggör utfallet av utnyttjande av teckningsoptioner av serie TO2

EJ FÖRPUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA, SYDKOREA,...

January 22, 2025

Abstract on the effect of STA363 on disc volume from the phase 1b study has been accepted for oral presentation at a major international congress

Stayble Therapeutics AB ("Stayble" or "the Company") announces that its scientific abstract on the effect of STA363 on disc volume reduction in patients with lumbar...

FINANCIAL CALENDAR

INTERIM REPORT Q4 2024
25February2025
Annual report 2024
7May2025
INTERIM REPORT Q1 2025
21May2025
Annual meeting 2025
5June2025
INTERIM REPORT Q2 2025
20August2025
INTERIM REPORT Q3 2025
19November2025
INTERIM REPORT Q4 2025
25February2026